Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Free Will, Determinism, and Intuitive Judgments About the Heritability of Behavior.

Willoughby EA, Love AC, McGue M, Iacono WG, Quigley J, Lee JJ.

Behav Genet. 2019 Mar;49(2):136-153. doi: 10.1007/s10519-018-9931-1. Epub 2018 Oct 12.

PMID:
30315376
2.

Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals.

Lee JJ, Wedow R, Okbay A, Kong E, Maghzian O, Zacher M, Nguyen-Viet TA, Bowers P, Sidorenko J, Karlsson Linnér R, Fontana MA, Kundu T, Lee C, Li H, Li R, Royer R, Timshel PN, Walters RK, Willoughby EA, Yengo L; 23andMe Research Team; COGENT (Cognitive Genomics Consortium); Social Science Genetic Association Consortium, Alver M, Bao Y, Clark DW, Day FR, Furlotte NA, Joshi PK, Kemper KE, Kleinman A, Langenberg C, Mägi R, Trampush JW, Verma SS, Wu Y, Lam M, Zhao JH, Zheng Z, Boardman JD, Campbell H, Freese J, Harris KM, Hayward C, Herd P, Kumari M, Lencz T, Luan J, Malhotra AK, Metspalu A, Milani L, Ong KK, Perry JRB, Porteous DJ, Ritchie MD, Smart MC, Smith BH, Tung JY, Wareham NJ, Wilson JF, Beauchamp JP, Conley DC, Esko T, Lehrer SF, Magnusson PKE, Oskarsson S, Pers TH, Robinson MR, Thom K, Watson C, Chabris CF, Meyer MN, Laibson DI, Yang J, Johannesson M, Koellinger PD, Turley P, Visscher PM, Benjamin DJ, Cesarini D.

Nat Genet. 2018 Jul 23;50(8):1112-1121. doi: 10.1038/s41588-018-0147-3.

3.

Importance of Intelligence and Emotional Intelligence for Physicians.

Willoughby E, Boutwell BB.

JAMA. 2018 Jul 10;320(2):205. doi: 10.1001/jama.2018.6278. No abstract available.

PMID:
29998331
4.

Incidence and prevalence of NMOSD in Australia and New Zealand.

Bukhari W, Prain KM, Waters P, Woodhall M, O'Gorman CM, Clarke L, Silvestrini RA, Bundell CS, Abernethy D, Bhuta S, Blum S, Boggild M, Boundy K, Brew BJ, Brown M, Brownlee WJ, Butzkueven H, Carroll WM, Chen C, Coulthard A, Dale RC, Das C, Dear K, Fabis-Pedrini MJ, Fulcher D, Gillis D, Hawke S, Heard R, Henderson APD, Heshmat S, Hodgkinson S, Jimenez-Sanchez S, Killpatrick T, King J, Kneebone C, Kornberg AJ, Lechner-Scott J, Lin MW, Lynch C, Macdonell R, Mason DF, McCombe PA, Pender MP, Pereira JA, Pollard JD, Reddel SW, Shaw C, Spies J, Stankovich J, Sutton I, Vucic S, Walsh M, Wong RC, Yiu EM, Barnett MH, Kermode AG, Marriott MP, Parratt JDE, Slee M, Taylor BV, Willoughby E, Wilson RJ, Vincent A, Broadley SA.

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):632-638. doi: 10.1136/jnnp-2016-314839. Epub 2017 May 26.

5.

Multiple Sclerosis impact on employment and income in New Zealand.

Pearson JF, Alla S, Clarke G, Mason DF, Anderson T, Richardson A, Miller DH, Sabel CE, Abernethy DA, Willoughby EW, Taylor BV.

Acta Neurol Scand. 2017 Sep;136(3):223-232. doi: 10.1111/ane.12714. Epub 2016 Nov 28.

PMID:
27891575
6.

Bariatric Surgery -A Viable Option and the Best Hope for Many Mississippians?

Willoughby EL, Jones ES, Minor DS.

J Miss State Med Assoc. 2016 Oct;58(10):329-331.

PMID:
30398762
7.

Disability profile of multiple sclerosis in New Zealand.

Alla S, Pearson JF, Taylor BV, Miller DH, Clarke G, Richardson A, Willoughby E, Abernethy DA, Sabel CE, Mason DF.

J Clin Neurosci. 2016 Jun;28:97-101. doi: 10.1016/j.jocn.2015.09.020. Epub 2016 Jan 4.

PMID:
26765754
8.

An investigation of the relationship between latitude and multiple sclerosis severity in New Zealand.

Alla S, Pearson JF, Taylor BV, Roxburgh R, Clarke G, Miller DH, Richardson A, Abernethy DA, Willoughby E, Sabel CE, Mason DF.

Mult Scler. 2016 Apr;22(5):705-7. doi: 10.1177/1352458515605909. Epub 2015 Oct 2. No abstract available.

PMID:
26432856
9.

A new era in the treatment of multiple sclerosis.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies JM, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E.

Med J Aust. 2015 Aug 3;203(3):139-41, 141e.1. Review.

PMID:
26224184
10.

Congestive myeloradiculopathy in a patient with Cowden syndrome.

Wu TY, Willoughby E, Hutchinson DO, Brew S, McGuinness B, Lopes R, Love DR, Roxburgh RH.

J Clin Neurosci. 2015 Feb;22(2):431-3. doi: 10.1016/j.jocn.2014.07.023. Epub 2014 Oct 7.

PMID:
25304432
11.

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E; MS Neurology Group of the Australian and New Zealand Association of Neurologists.

J Clin Neurosci. 2014 Nov;21(11):1857-65. doi: 10.1016/j.jocn.2014.01.017. Epub 2014 Jun 30. Review.

PMID:
24993136
12.

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E; MS Neurology Group of the Australian and New Zealand Association of Neurologists.

J Clin Neurosci. 2014 Nov;21(11):1835-46. doi: 10.1016/j.jocn.2014.01.016. Epub 2014 Jun 30. Review.

PMID:
24993135
13.

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E; MS Neurology Group of the Australian and New Zealand Association of Neurologists.

J Clin Neurosci. 2014 Nov;21(11):1847-56. doi: 10.1016/j.jocn.2014.01.018. Epub 2014 Jun 28. Review.

PMID:
24986155
14.

Assessing possible selection bias in a national voluntary MS longitudinal study in Australia.

Taylor BV, Palmer A, Simpson S Jr, Lucas R; NZMSPS study group, Simmons RD, Mason D, Pearson J, Clarke G, Sabel C, Willoughby E, Richardson A, Abernethy D.

Mult Scler. 2013 Oct;19(12):1627-31. doi: 10.1177/1352458513481511. Epub 2013 Mar 25.

PMID:
23530001
15.

Neurological manifestations of phaeochromocytomas and secretory paragangliomas: a reappraisal.

Anderson NE, Chung K, Willoughby E, Croxson MS.

J Neurol Neurosurg Psychiatry. 2013 Apr;84(4):452-7. doi: 10.1136/jnnp-2012-303028. Epub 2012 Dec 1.

PMID:
23204473
16.

Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci.

Patsopoulos NA; Bayer Pharma MS Genetics Working Group; Steering Committees of Studies Evaluating IFNβ-1b and a CCR1-Antagonist; ANZgene Consortium; GeneMSA; International Multiple Sclerosis Genetics Consortium, Esposito F, Reischl J, Lehr S, Bauer D, Heubach J, Sandbrink R, Pohl C, Edan G, Kappos L, Miller D, Montalbán J, Polman CH, Freedman MS, Hartung HP, Arnason BG, Comi G, Cook S, Filippi M, Goodin DS, Jeffery D, O'Connor P, Ebers GC, Langdon D, Reder AT, Traboulsee A, Zipp F, Schimrigk S, Hillert J, Bahlo M, Booth DR, Broadley S, Brown MA, Browning BL, Browning SR, Butzkueven H, Carroll WM, Chapman C, Foote SJ, Griffiths L, Kermode AG, Kilpatrick TJ, Lechner-Scott J, Marriott M, Mason D, Moscato P, Heard RN, Pender MP, Perreau VM, Perera D, Rubio JP, Scott RJ, Slee M, Stankovich J, Stewart GJ, Taylor BV, Tubridy N, Willoughby E, Wiley J, Matthews P, Boneschi FM, Compston A, Haines J, Hauser SL, McCauley J, Ivinson A, Oksenberg JR, Pericak-Vance M, Sawcer SJ, De Jager PL, Hafler DA, de Bakker PI.

Ann Neurol. 2011 Dec;70(6):897-912. doi: 10.1002/ana.22609. Erratum in: Ann Neurol. 2013 Apr;73(4):561.

17.

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.

International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, Edkins S, Gray E, Booth DR, Potter SC, Goris A, Band G, Oturai AB, Strange A, Saarela J, Bellenguez C, Fontaine B, Gillman M, Hemmer B, Gwilliam R, Zipp F, Jayakumar A, Martin R, Leslie S, Hawkins S, Giannoulatou E, D'alfonso S, Blackburn H, Martinelli Boneschi F, Liddle J, Harbo HF, Perez ML, Spurkland A, Waller MJ, Mycko MP, Ricketts M, Comabella M, Hammond N, Kockum I, McCann OT, Ban M, Whittaker P, Kemppinen A, Weston P, Hawkins C, Widaa S, Zajicek J, Dronov S, Robertson N, Bumpstead SJ, Barcellos LF, Ravindrarajah R, Abraham R, Alfredsson L, Ardlie K, Aubin C, Baker A, Baker K, Baranzini SE, Bergamaschi L, Bergamaschi R, Bernstein A, Berthele A, Boggild M, Bradfield JP, Brassat D, Broadley SA, Buck D, Butzkueven H, Capra R, Carroll WM, Cavalla P, Celius EG, Cepok S, Chiavacci R, Clerget-Darpoux F, Clysters K, Comi G, Cossburn M, Cournu-Rebeix I, Cox MB, Cozen W, Cree BA, Cross AH, Cusi D, Daly MJ, Davis E, de Bakker PI, Debouverie M, D'hooghe MB, Dixon K, Dobosi R, Dubois B, Ellinghaus D, Elovaara I, Esposito F, Fontenille C, Foote S, Franke A, Galimberti D, Ghezzi A, Glessner J, Gomez R, Gout O, Graham C, Grant SF, Guerini FR, Hakonarson H, Hall P, Hamsten A, Hartung HP, Heard RN, Heath S, Hobart J, Hoshi M, Infante-Duarte C, Ingram G, Ingram W, Islam T, Jagodic M, Kabesch M, Kermode AG, Kilpatrick TJ, Kim C, Klopp N, Koivisto K, Larsson M, Lathrop M, Lechner-Scott JS, Leone MA, Leppä V, Liljedahl U, Bomfim IL, Lincoln RR, Link J, Liu J, Lorentzen AR, Lupoli S, Macciardi F, Mack T, Marriott M, Martinelli V, Mason D, McCauley JL, Mentch F, Mero IL, Mihalova T, Montalban X, Mottershead J, Myhr KM, Naldi P, Ollier W, Page A, Palotie A, Pelletier J, Piccio L, Pickersgill T, Piehl F, Pobywajlo S, Quach HL, Ramsay PP, Reunanen M, Reynolds R, Rioux JD, Rodegher M, Roesner S, Rubio JP, Rückert IM, Salvetti M, Salvi E, Santaniello A, Schaefer CA, Schreiber S, Schulze C, Scott RJ, Sellebjerg F, Selmaj KW, Sexton D, Shen L, Simms-Acuna B, Skidmore S, Sleiman PM, Smestad C, Sørensen PS, Søndergaard HB, Stankovich J, Strange RC, Sulonen AM, Sundqvist E, Syvänen AC, Taddeo F, Taylor B, Blackwell JM, Tienari P, Bramon E, Tourbah A, Brown MA, Tronczynska E, Casas JP, Tubridy N, Corvin A, Vickery J, Jankowski J, Villoslada P, Markus HS, Wang K, Mathew CG, Wason J, Palmer CN, Wichmann HE, Plomin R, Willoughby E, Rautanen A, Winkelmann J, Wittig M, Trembath RC, Yaouanq J, Viswanathan AC, Zhang H, Wood NW, Zuvich R, Deloukas P, Langford C, Duncanson A, Oksenberg JR, Pericak-Vance MA, Haines JL, Olsson T, Hillert J, Ivinson AJ, De Jager PL, Peltonen L, Stewart GJ, Hafler DA, Hauser SL, McVean G, Donnelly P, Compston A.

Nature. 2011 Aug 10;476(7359):214-9. doi: 10.1038/nature10251.

18.

American academy of neurology annual meeting.

Willoughby E.

Int MS J. 2011 May;17(2):69-70.

PMID:
21689501
19.

Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis.

Phillips JT, Giovannoni G, Lublin FD, O'Connor PW, Polman CH, Willoughby E, Aschenbach W, Pace A, Hyde R, Munschauer FE.

Mult Scler. 2011 Aug;17(8):970-9. doi: 10.1177/1352458511399611. Epub 2011 Mar 18.

PMID:
21421809
20.

Pseudoislets as primary islet replacements for research: report on a symposium at King's College London, London UK.

Persaud SJ, Arden C, Bergsten P, Bone AJ, Brown J, Dunmore S, Harrison M, Hauge-Evans A, Kelly C, King A, Maffucci T, Marriott CE, McClenaghan N, Morgan NG, Reers C, Russell MA, Turner MD, Willoughby E, Younis MY, Zhi ZL, Jones PM.

Islets. 2010 Jul-Aug;2(4):236-9.

PMID:
21137597
21.

MS prevalence in New Zealand, an ethnically and latitudinally diverse country.

Taylor BV, Pearson JF, Clarke G, Mason DF, Abernethy DA, Willoughby E, Sabel C.

Mult Scler. 2010 Dec;16(12):1422-31. doi: 10.1177/1352458510379614. Epub 2010 Sep 2.

PMID:
20813774
22.
23.

A randomized controlled trial of cognitive behavior therapy for multiple sclerosis fatigue.

van Kessel K, Moss-Morris R, Willoughby E, Chalder T, Johnson MH, Robinson E.

Psychosom Med. 2008 Feb;70(2):205-13. doi: 10.1097/PSY.0b013e3181643065. Epub 2008 Feb 6.

PMID:
18256342
24.

Dynamic interaction between the dual specificity phosphatase MKP7 and the JNK3 scaffold protein beta-arrestin 2.

Willoughby EA, Collins MK.

J Biol Chem. 2005 Jul 8;280(27):25651-8. Epub 2005 May 10.

25.

Maternal rank and local resource competition do not predict birth sex ratios in wild baboons.

Silk JB, Willoughby E, Brown GR.

Proc Biol Sci. 2005 Apr 22;272(1565):859-64.

26.

The JNK-interacting protein-1 scaffold protein targets MAPK phosphatase-7 to dephosphorylate JNK.

Willoughby EA, Perkins GR, Collins MK, Whitmarsh AJ.

J Biol Chem. 2003 Mar 21;278(12):10731-6. Epub 2003 Jan 10.

27.

Modafinil for fatigue in multiple sclerosis.

Willoughby E.

J Neurol Neurosurg Psychiatry. 2002 Feb;72(2):150. No abstract available.

28.

Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group.

Ahrens SP, Farmer MV, Williams DL, Willoughby E, Jiang K, Block GA, Visser WH.

Cephalalgia. 1999 Jun;19(5):525-30.

PMID:
10403069
29.

Development of a multiple sclerosis functional composite as a clinical trial outcome measure.

Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, Syndulko K, Weinshenker BG, Antel JP, Confavreux C, Ellison GW, Lublin F, Miller AE, Rao SM, Reingold S, Thompson A, Willoughby E.

Brain. 1999 May;122 ( Pt 5):871-82.

PMID:
10355672
30.

Idiopathic steroid responsive chronic lymphocytic meningitis--clinical features and long-term outcome in 17 patients.

Charleston AJ, Anderson NE, Willoughby EW.

Aust N Z J Med. 1998 Dec;28(6):784-9.

PMID:
9972407
31.

Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group.

Teall J, Tuchman M, Cutler N, Gross M, Willoughby E, Smith B, Jiang K, Reines S, Block G.

Headache. 1998 Apr;38(4):281-7.

PMID:
9595867
32.

Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force.

Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby E.

Ann Neurol. 1997 Sep;42(3):379-82.

PMID:
9307263
33.

Late recurrence of postdural puncture headache.

Sidebotham D, Willoughby E, Schug SA.

Reg Anesth. 1997 Jul-Aug;22(4):382-4.

PMID:
9223207
34.

Clinical outcomes assessment in multiple sclerosis.

Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby E.

Ann Neurol. 1996 Sep;40(3):469-79. Review.

PMID:
8797541
35.

Leptomeningeal and brain biopsy in chronic meningitis.

Anderson NE, Willoughby EW, Synek BJ.

Aust N Z J Med. 1995 Dec;25(6):703-6.

PMID:
8770335
36.

A structured panel interview and group exercise in the selection of medical students.

Collins JP, White GR, Petrie KJ, Willoughby EW.

Med Educ. 1995 Sep;29(5):332-6.

PMID:
8699969
37.

Brain biopsy in the management of focal encephalitis.

Anderson NE, Willoughby EW, Synek BJ, Croxson MC, Glasgow GL.

J Neurol Neurosurg Psychiatry. 1991 Nov;54(11):1001-3.

38.

Myalgic encephalomyelitis.

Willoughby E.

N Z Med J. 1989 Jan 25;102(860):19-20. No abstract available.

PMID:
2913521
39.

Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients.

Willoughby EW, Grochowski E, Li DK, Oger J, Kastrukoff LF, Paty DW.

Ann Neurol. 1989 Jan;25(1):43-9.

PMID:
2913928
40.

Myalgic encephalomyelitis.

Willoughby EW.

N Z Med J. 1988 Nov 9;101(857):773. No abstract available.

PMID:
3186037
41.

Scales for rating impairment in multiple sclerosis: a critique.

Willoughby EW, Paty DW.

Neurology. 1988 Nov;38(11):1793-8.

PMID:
3185917
42.

Changes in immune function in relapsing multiple sclerosis correlate with disease activity as assessed by magnetic resonance imaging.

Oger J, O'Gorman M, Willoughby E, Li D, Paty DW.

Ann N Y Acad Sci. 1988;540:597-601. No abstract available.

PMID:
2974690
43.

Nystagmus and alcohol intoxication.

Willoughby EW.

N Z Med J. 1987 Oct 14;100(833):640. No abstract available.

PMID:
3452125
44.

Infarction of the conus medullaris.

Anderson NE, Willoughby EW.

Ann Neurol. 1987 May;21(5):470-4.

PMID:
3592640
45.

Chronic meningitis without predisposing illness--a review of 83 cases.

Anderson NE, Willoughby EW.

Q J Med. 1987 Apr;63(240):283-95. Review.

PMID:
3317475
46.

The natural history of syringomyelia.

Anderson NE, Willoughby EW, Wrightson P.

Clin Exp Neurol. 1986;22:71-80.

PMID:
3581513
47.

The natural history and the influence of surgical treatment in syringomyelia.

Anderson NE, Willoughby EW, Wrightson P.

Acta Neurol Scand. 1985 Jun;71(6):472-9.

PMID:
4024858
48.

Lower cranial nerve motor function in unilateral vascular lesions of the cerebral hemisphere.

Willoughby EW, Anderson NE.

Br Med J (Clin Res Ed). 1984 Sep 29;289(6448):791-4.

49.

The crossed upgoing toe sign: a clinical study.

Willoughby EW, Eason R.

Ann Neurol. 1983 Oct;14(4):480-2.

PMID:
6638959
50.

A sensitive silver stain for proteins in agarose gels.

Willoughby EW, Lambert A.

Anal Biochem. 1983 Apr 15;130(2):353-8.

PMID:
6191595

Supplemental Content

Loading ...
Support Center